| Humira (adalimumab) / AbbVie |
ChiCTR2000034388: Phase I clinical study of pharmacokinetics of recombinant human anti-tumor necrosis factor (TNF - α) monoclonal antibody injection and salmeterol |
|
|
| Recruiting | 1 | 162 | | TNF-a 40mg ;humira 40mg | Phase I Clinical Laboratory of Affiliated Hospital of Changchun University of Traditional Chinese Medicine; New Drug Research&Development Company of NCPC (North China Pharmaceutical Group Corporation), National major special projects and self financing | Rheumatoid arthritis, Psoriasis, Ankylosing Spondylitis | | | | |
NCT05884242: A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge |
|
|
| Completed | 1 | 20 | Europe | Adalimumab, Humira, Lipopolysaccharide (LPS) | Janssen Research & Development, LLC | Healthy | 08/23 | 08/23 | | |
| Not yet recruiting | 1 | 30 | Europe | Adalimumab-800CW, Humira, Fluorescence Imaging | University Medical Center Groningen, AbbVie | IBD, Rheumatoid Arthritis | 06/24 | 12/24 | | |
ChiCTR2300074787: A Multicenter, Prospective Clinical Study of the Effect of Adalimumab Trough Drug Concentration on Predicting Efficacy in Crohn's Disease |
|
|
| Recruiting | 1 | 30 | | Expected treatment regimen of adalimumab stem: Week 0, 160 mg; Week 2, 80 mg; followed by 40 mg every 2 weeks. The course of treatment was 24 weeks. | Tangdu Hospital, Fourth Military Medical University; Tangdu Hospital, Fourth Military Medical University, Self-financing | Crohn's disease | | | | |
